

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF      Art Unit: 1612  
Wagner, Jürgen et al.      Examiner: Webb, Walter E  
INTERNATIONAL APPLICATION NO: PCT/EP2005/003663  
FILED: April 07, 2005  
U.S. APPLICATION NO: 10/599697  
35 USC §371 DATE: October 05, 2006  
FOR: Protein Kinase C Inhibitors for the Treatment of Autoimmune  
Diseases and of Transplant Rejection

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,



Leslie Fischer  
Attorney for Applicant  
Reg. No. 58,393

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-9308

Date: 12/1/10